Creutzfeldt-Jakob disease (CJD) is a rare, fatal brain disorder caused by misfolded proteins called prions. It affects roughly 1 to 2 people per million each year worldwide, and once symptoms appear, the disease progresses rapidly. Most people with the sporadic form survive only 4 to 5 months after onset.
CJD belongs to a family of diseases called transmissible spongiform encephalopathies. The name comes from what the brain looks like under a microscope: riddled with tiny holes, like a sponge. Those holes form as misfolded prion proteins accumulate and destroy brain tissue, leading to swift neurological decline.
How Prions Damage the Brain
Your brain naturally produces a protein called prion protein, which sits on the surface of nerve cells. In CJD, this protein folds into an abnormal shape. The misfolded version then acts like a template, converting nearby normal proteins into the same broken shape. This chain reaction builds up clusters of damaged protein that nerve cells can’t clear away.
As these clusters grow, they punch holes through brain tissue, creating the sponge-like pattern that defines prion diseases. Unlike bacteria or viruses, prions contain no DNA or RNA. They’re just proteins, which makes them extraordinarily hard to destroy. Standard sterilization methods that kill bacteria and viruses don’t work on prions. Hospitals dealing with suspected CJD cases must use extreme measures: soaking instruments in concentrated sodium hydroxide or bleach solutions, then autoclaving them at high temperatures for extended periods. In some cases, surgical tools are simply destroyed after use.
Three Types of CJD
About 85% of CJD cases are sporadic, meaning they appear without any identifiable cause. The misfolded proteins seem to arise spontaneously, and the typical age of onset is around 68. No one knows exactly what triggers this process.
Between 5% and 15% of cases are familial, caused by inherited mutations in the gene that codes for prion protein (known as the PRNP gene). More than 30 distinct mutations in this gene have been linked to genetic CJD. If a parent carries one of these mutations, each child has a 50% chance of inheriting it.
Less than 1% of cases are acquired from an external source. This category includes iatrogenic CJD, which results from accidental exposure to prions during medical procedures, and variant CJD, the form linked to consuming beef from cattle infected with bovine spongiform encephalopathy, commonly known as mad cow disease. Variant CJD is notable for striking much younger people, with an average age of onset around 28, and it follows a slower course, with a median illness duration of 13 to 14 months.
Early Symptoms
The first signs of sporadic CJD are often vague enough to be mistaken for other conditions. People may experience vertigo, headaches, fatigue, or sleep problems. Memory difficulties, mood swings, irritability, depression, and visual changes can also appear early on. Because these symptoms overlap with so many other neurological and psychiatric conditions, CJD is rarely the first diagnosis considered.
Variant CJD tends to begin differently. Early symptoms are more likely to be psychiatric, including anxiety, depression, and behavioral changes, sometimes lasting months before any obvious neurological signs develop.
How the Disease Progresses
Once CJD takes hold, the decline is rapid and devastating. Confusion and disorientation worsen quickly. Most people develop problems with coordination and movement: difficulty walking, muscle stiffness, and involuntary jerking movements called myoclonus. These jerks can persist during sleep and may be triggered by loud sounds or bright lights.
Over weeks to months, patients lose the ability to move independently and to speak. Eventually, they enter a comatose state. For sporadic CJD, death typically occurs within a year, with most people surviving about 4 to 5 months from the time symptoms become apparent. The speed of this decline is one of the features that distinguishes CJD from other forms of dementia, which usually progress over years rather than months.
How CJD Is Diagnosed
Diagnosing CJD relies on a combination of clinical evaluation, brain imaging, and lab tests. No single test confirms the disease with certainty during life, so doctors look for a pattern of evidence.
Brain MRI is one of the most useful tools. In CJD, specific areas of the brain light up on certain types of MRI scans. A characteristic finding called the “cortical ribbon sign” shows abnormal signal along the outer layers of the brain, typically in at least two separate regions. Deeper structures, particularly the caudate nucleus and putamen, also show changes. These MRI patterns can appear early in the disease and help distinguish CJD from other causes of rapid cognitive decline.
A spinal fluid test can detect a protein marker called 14-3-3, which leaks out of damaged brain cells. This test has a sensitivity of about 92% and a specificity of about 80%, meaning it catches most true cases but can occasionally produce false positives in people with other brain injuries. Newer spinal fluid tests have been developed that can directly detect the presence of misfolded prion proteins, offering greater diagnostic confidence.
Genetic testing of the PRNP gene can identify familial forms. A definitive diagnosis, however, still requires examining brain tissue, either through biopsy or after death.
Treatment and Outlook
There is currently no cure for CJD and no treatment that slows its progression. Care focuses on managing symptoms and keeping the person as comfortable as possible. Medications can help control myoclonus, agitation, and pain, but they don’t alter the course of the disease.
Research into potential treatments is ongoing but has faced significant challenges. One clinical trial investigated a drug delivered directly into the spinal fluid to reduce prion protein production, but that trial has closed to new enrollment. The fundamental difficulty is that by the time symptoms appear, extensive brain damage has already occurred, and prions are notoriously resistant to intervention.
For families, the rapid progression of CJD means that conversations about care preferences and end-of-life planning become urgent soon after diagnosis. Many families find themselves moving from initial symptoms to hospice care within a matter of months, a timeline that can feel overwhelming. Early involvement of palliative care teams can help manage both the physical symptoms and the emotional weight of the disease.
Who Is at Risk
For the sporadic form, which accounts for the vast majority of cases, there are no known risk factors beyond age. It most commonly appears in people in their late 60s. You cannot catch sporadic CJD from casual contact with someone who has it, and it does not spread through coughing, sneezing, or sexual contact.
People with a family history of prion disease may carry PRNP mutations that increase their risk. Genetic counseling is available for families with known mutations, though carrying a mutation does not guarantee the disease will develop.
The risk of variant CJD from contaminated beef has dropped dramatically since the 1990s, when countries implemented strict controls on cattle feed and slaughterhouse practices. The vast majority of variant CJD cases were linked to exposure in the United Kingdom during the BSE epidemic, and new cases have become extremely rare worldwide.